Please assess the completion status of the following clinical trial:

Trial Title: ELITE: Early Versus Late Intervention Trial With Estradiol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women with a serum estradiol level 25 pg/ml or less~* No period for 6 months or more~* Postmenopausal less than 6 years, OR 10 years or longer~Exclusion Criteria:~* Clinical signs, symptoms, or personal history of cardiovascular disease~* Women who have had a hysterectomy only and no oophorectomy (since time from menopause cannot be determined)~* Diabetes mellitus or fasting serum glucose 140 mg/dL or greater~* Uncontrolled hypertension (diastolic blood pressure 110 mmHg or greater)~* Thyroid disease (untreated)~* Serum creatinine greater than 2.0 mg/dL~* Plasma triglyceride levels greater than 500 mg/dL~* Life threatening disease with prognosis less than 5 years~* Cirrhosis or liver disease~* History of deep vein thrombosis or pulmonary embolism~* History of breast cancer~* Current hormone replacement therapy (HRT)

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 17B-estradiol (Type: ACTIVE_COMPARATOR): Oral 17B-estradiol 1 mg daily
- Placebo (Type: PLACEBO_COMPARATOR): Matching oral 17B-estradiol placebo daily

Based on this trial design, predict the completion outcome and termination type (if applicable).